Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

For millions of individuals, life with sickle cell disease (SCD) doesn’t unfold in dramatic episodes—it wears on quietly, ...

Sickle crises are the most common complication of sickle cell anemia. [ 4 ] The pain of a sickle cell crisis starts suddenly and may last anywhere from hours to weeks.

Extreme pain, known as a pain crisis, is one of the hallmark symptoms of SCD. With frequent hospitalizations, chronic pain and damage to vital organs, people living with SCD often experience a greatly ...

A researcher at Duke University, speaks out after her NIH grant for sickle cell research was terminated. The $750,000 funding ...

Over a hundred sickle cell warriors and their families turned out in support for World Sickle Cell Day at West Oakland’s DeFremery Park on Sunday.

This patient's initial painful crisis may have been induced by paclitaxel. The mechanism for this is not well-known. In the literature, there are data to suggest that paclitaxel can affect plasma ...

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

Sickle cell is now the fastest growing genetic condition in the United Kingdom and can cause organ damage and strokes.

Around 2,500 people are living with sickle cell disease in the Bay State, and they are advocating for a bill that would improve quality of life for all those dealing with the disease.

Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why BEAM stock is a Strong Buy.